Zenas BioPharma, Inc. Income Statement
ZBIO / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Zenas BioPharma, Inc. reported $10M in revenue and $378M in net loss for FY2025. Revenue has declined at a 55.3% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $10.0M | $50.0M | $50.0M |
| SG&A Expense | $53.3M | $17.1M | $17.1M |
| R&D Expense | $168.1M | $60.0M | $60.0M |
| Operating Income | -$383.1M | -$37.1M | -$37.1M |
| Income Tax | -$79.0K | $301.0K | $301.0K |
| Net Income | -$377.7M | -$37.1M | -$37.1M |
| EPS (Basic) | -$11.89 | -$24.25 | -$24.25 |
| EPS (Diluted) | -$11.89 | -$24.25 | -$24.25 |
| Shares Outstanding | 41.8M | 1.6M | 1.5M |
| Operating Margin | -3830.6% | -74.3% | -74.3% |
| Profit Margin | -3777.4% | -74.3% | -74.3% |